Rakuten Medical, Inc.
900 Concar Dr, Suite 200
38 articles with Rakuten Medical, Inc.
Rakuten Medical, Inc. has elected to discontinue use of the name "Illuminox," and to start using a new, evolved name "Alluminox™" for our proprietary, anti-cancer, photoimmunotherapy technology platform, which is comprised of drug, medical device, and other related technologies.
Rakuten Medical, Inc. (Rakuten Medical) and Shimadzu Corporation (Shimadzu) today announced enrollment of the first patient in the phase 2 clinical trial of ASP-1929 photoimmunotherapy with fluorescence imaging (Study number: ASP-1929-103) at the National Cancer Institute of the National Institutes of Health in the United States.
Rakuten Medical to Present at the 40th Annual J.P. Morgan Healthcare Conference on January 10th, 2022
Rakuten Medical, Inc., a global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox™, will present at the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10-13, 2022.
Rakuten Medical Announces FDA Acceptance of an Investigational New Drug (IND) Application for RM-1995, a Conjugate of IR700 and anti-CD25 Antibody
Rakuten Medical, Inc announced that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug application to begin clinical studies of RM-1995 photoimmunotherapy in patients with advanced cutaneous squamous cell carcinoma or with head and neck squamous cell carcinoma.
Data from Phase 1/2a study of RM-1929 Photoimmunotherapy in Patients with Recurrent Head and Neck Squamous Cell Carcinoma was Published in Head and Neck
Rakuten Medical, Inc. announced that data from a phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma was accepted for publication in Head and Neck and published online on October 9th, 2021.
Rakuten Medical and Karkinos Healthcare Announce Strategic Partnership to Expand the Reach of Novel Cancer Care in India
Rakuten Medical Inc, and Karkinos Healthcare Private Limited announced a strategic collaboration to expand the reach of novel cancer care to India.
Show me the money! This week's who's who of IPOs and financing rounds in the biopharma world.
Financing will support Rakuten Medical's ongoing trials of ASP-1929 in several oncologic indications and research and development of additional pipeline therapies being developed using the Illuminox™ platform.
Three major pharmaceutical and biotechnology companies announce the success of their respective funding rounds to support future efforts.
Rakuten Medical, Inc., a global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox™, will present at the 39th Annual J.P. Morgan Healthcare Conference being held virtually January 11-14, 2021.
Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
Rakuten Medical, Inc. announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors has enrolled and treated its first patient in the United States, at The University of Texas MD Anderson Cancer Center, Houston, Texas.
Rakuten Medical Japan Announces Marketing Approval of Akalux® IV Infusion 250mg and BioBlade® Laser System from the Ministry of Labour, Health and Welfare in Japan for Locoregional Cancer Treatment
Rakuten Medical Inc. is proud to announce that its wholly owned subsidiary Rakuten Medical Japan K.K. has received marketing approval in Japan from the Ministry of Health, Labour and Welfare for Akalux® IV Infusion 250mg (cetuximab saratolacan sodium) to treat unresectable locally advanced or recurrent head and neck cancer.
Rakuten Medical, Inc. announced today the acquisition of Medlight SA. Medlight produces and commercializes a large range of catheters and diffusers for optical light delivery. The terms of
Rakuten Medical closes deal with Merck KGaA, Darmstadt, Germany to receive cetuximab for production of Rakuten Medical's ASP-1929 antibody-drug conjugate
Rakuten Medical, Inc. (Rakuten Medical) announced they have entered a multi-year deal with Merck KGaA, Darmstadt, Germany under which Merck KGaA, Darmstadt, Germany will provide cetuximab to Rakuten Medical for its ASP-1929 program. Rakuten Medical uses cetuximab in an intermediate form as the antibody component in its product c
Rakuten Medical Receives Conditional Early Approval Designation from Japanese Health Ministry for its Lead Drug, ASP-1929, to Treat Recurrent Head & Neck Cancer
Rakuten Medical, Inc. (Rakuten Medical) today announced that the Japanese Ministry of Health, Labor, and Welfare (MHLW) has notified Rakuten Medical that its lead drug ASP-1929 will be reviewed under the Conditional Early Approval System (CEAS). Compared to standard review the CEAS speeds up the approval process, bringing potentia
Rakuten Medical Presents Data Characterizing how Photoimmunotherapy Induces Cancer Cell Death and Enhances the Immune Response Preclinically
Rakuten Medical, Inc. (Rakuten Medical) today announced the results of two preclinical studies presented at the American Association for Cancer Research (AACR) Virtual Meeting II. These studies further demonstrate t
Rakuten Medical and MD Anderson Announce Strategic Alliance to Advance Illuminox Platform for Cancer Treatments
Rakuten Medical, Inc. (Rakuten Medical) and The University of Texas MD Anderson Cancer Center (MD Anderson) today announced a strategic alliance collaboration agreement to advance the development of new cancer therapies based on Rakuten Medical's proprietary Illuminox ™ technology platform.
Rakuten Medical Establishes Illuminox™ Alliance Institutes to Accelerate Development of Cancer Therapies, Announcing The National Cancer Center Japan as the First Institute to Join the Alliance
Rakuten Medical, Inc. (Rakuten Medical), a global biotechnology company developing precision, cell-targeting investigational therapies on its Illuminox™ technology platform, established a strategic cancer research alliance network, the Illuminox Alliance Institutes (IAI), in order to advance the development of new cancer therapies.
Rakuten Medical, Inc. (RMI) a clinical-stage, global biotechnology company developing precision-targeted cancer therapies based on its proprietary, anti-cancer treatment platform, Illuminox™, will present at the 38th Annual J.P. Morgan Healthcare Conference being held January 13-16, 2020, in San Francisco.
Rakuten Medical appoints David Chao and Kentaro Hyakuno to its Board of Directors, Welcomes new CFO and General Counsel to Executive Leadership Team
Rakuten Medical has appointed two new directors to the company's Board: David Chao, co-founder and General Partner of DCM Ventures; and Kentaro Hyakuno, Chief Operating Officer and Group Executive Vice President of Rakuten, Inc.